Skip Nav Destination
Letter|
June 7, 2024
Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy
Laura N Eadie
Laura N Eadie
South Australian Health and Medical Research Institute, Adelaide, Australia
https://orcid.org/0000-0003-1912-7602
Search for other works by this author on:
Elias Lagonik
Elias Lagonik
South Australian Health and Medical Research Institute, Adelaide, Australia
Search for other works by this author on:
Elyse C Page
Elyse C Page
South Australian Health and Medical Research Institute, Adelaide, Australia
Search for other works by this author on:
Susan L Heatley
Susan L Heatley
South Australian Health & Medical Research Institute, Adelaide, Australia
Search for other works by this author on:
Barbara J McClure
Barbara J McClure
The University of Adelaide, Australia
Search for other works by this author on:
David T Yeung
David T Yeung
South Australian Health and Medical Research Institute, Adelaide, Australia
Search for other works by this author on:
Deborah L White
SAHMRI, Adelaide, Australia
Search for other works by this author on:
Blood blood.2024024776.
Article history
Submitted:
March 25, 2024
Revision Received:
May 24, 2024
Accepted:
May 30, 2024
Don't already have an account? Create Account
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal